The molecular basis of myeloid malignancies

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 90, Issue 10, 2014, Pages 389-404

  Kitamura, Toshio ^a   Inoue, Daichi ^a   Okochi Watanabe, Naoko ^a   Kato, Naoko ^a   Komeno, Yukiko ^a   Lu, Yang ^a   Enomoto, Yutaka ^a   Doki, Noriko ^a   Uchida, Tomoyuki ^a   Kagiyama, Yuki ^a   Togami, Katsuhiro ^a   Kawabata, Kimihito ^a   Nagase, Reina ^a   Horikawa, Sayuri ^a   Hayashi, Yasutaka ^a   Saika, Makoto ^a   Fukuyama, Tomofusa ^a   Izawa, Kumi ^a   Oki, Toshihiko ^a   Nakahara, Fumio ^a   Kitaura, Jiro ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute myeloid leukemia; Epigenetic factors; Mutations; Myelodysplastic syndromes; Myeloproliferative neoplasm; Splicing

Indexed keywords

BCR ABL PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS; HEMATOLOGIC DISEASE; HUMAN; METABOLISM; MOUSE; MUTATION; MYELODYSPLASTIC SYNDROME;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; FUSION PROTEINS, BCR-ABL; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MUTATION; MYELODYSPLASTIC SYNDROMES;

EID: 84923839103     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.90.389     Document Type: Review

References (97)

1. Bartram, C.R., de Klein, A., Hagemeijer, A., van Agthoven, T., Geurts van Kessel, A., Bootsma, D., Grosveld, G., Ferguson-Smith, M.A., Davies, T., Stone, M., Heisterkamp, N., Stephenson, J.R. and Groffen, J. (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306, 277-280.
2. Wong, S. and Witte, O.N. (2001) Modeling Philadelphia chromosome positive leukemias. Oncogene 20, 5644-5659.
3. Van Etten, R.A. (2001) Retroviral transduction models of PhD leukemia: advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol. Dis. 27, 201-205.
4. Grisolano, J.L., Wesselschmidt, R.L., Pelicci, P.G. and Ley, T.J. (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89, 376-387.
5. Kelly, L.M., Kutok, J.L., Williams, I.R., Boulton, C.L., Amaral, S.M., Curley, D.P., Ley, T.J. and Gilliland, D.G. (2002) PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. U.S.A. 99, 8283-8288.
6. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. and Gilliland, D.G. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99, 310-318.
7. Gilliland, D.G. and Griffin, J.D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532-1542.
8. Stubbs, M.C., Kim, Y.M., Krivtsov, A.V., Wright, R.D., Feng, Z., Agarwal, J., Kung, A.L. and Armstrong, S.A. (2008) MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 22, 66-77.
9. Moriya, K., Suzuki, M., Watanabe, Y., Takahashi, T., Aoki, Y., Uchiyama, T., Kumaki, S., Sasahara, Y., Minegishi, M., Kure, S., Tsuchiya, S., Sugamura, K. and Ishii, N. (2012) Development of a multi-step leukemogenesis model of MLLrearranged leukemia using humanized mice. PLoS ONE 7, e37892.
10. Ono, R., Kumagai, H., Nakajima, H., Hishiya, A., Taki, T., Horikawa, K., Takatsu, K., Satoh, T., Hayashi, Y., Kitamura, T. and Nosaka, T. (2009) Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia 23, 2197-2209.
11. Ono, R., Nakajima, H., Ozaki, K., Kumagai, H., Kawashima, T., Taki, T., Kitamura, T., Hayashi, Y. and Nosaka, T. (2005) Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J. Clin. Invest. 115, 919-929.
12. Nick, H.J., Kim, H.G., Chang, C.W., Harris, K.W., Reddy, V. and Klug, C.A. (2012) Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood 119, 1522-1531.
13. Kagiyama, Y., Kitaura, J., Togami, K., Uchida, T., Inoue, D., Matsukawa, T., Izawa, K., Kawabata, K.C., Komeno, Y., Oki, T., Nakahara, F., Sato, K., Aburatani, H. and Kitamura, T. (2012) Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice. Int. J. Hematol. 96, 638-648.
14. Gilliland, D.G. (2001) Hematologic malignancies. Curr. Opin. Hematol. 8, 189-191.
15. Ye, M., Zhang, H., Amabile, G., Yang, H., Staber, P.B., Zhang, P., Levantini, E., Alberich-Jorda, M., Zhang, J., Kawasaki, A. and Tenen, D.G. (2013) C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence. Nat. Cell Biol. 15, 385-394.
16. Nerlov, C. (2004) C/EBPalpha mutations in acute myeloid leukaemias. Nat. Rev. Cancer 4, 394-400.
17. Pabst, T. and Mueller, B.U. (2007) Transcriptional dysregulation during myeloid transformation in AML. Oncogene 26, 6829-6837.
18. Bereshchenko, O., Mancini, E., Moore, S., Bilbao, D., Mansson, R., Luc, S., Grover, A., Jacobsen, S.E., Bryder, D. and Nerlov, C. (2009) Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 16, 390-400.
19. Kato, N., Kitaura, J., Doki, N., Komeno, Y., Watanabe-Okochi, N., Togami, K., Nakahara, F., Oki, T., Enomoto, Y., Fukuchi, Y., Nakajima, H., Harada, Y., Harada, H. and Kitamura, T. (2011) Two types of C/EBPalpha mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood 117, 221-233.
20. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. and Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397.
21. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. and Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148.
22. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. and Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061.
23. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. and Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790.
24. Tiedt, R., Hao-Shen, H., Sobas, M.A., Looser, R., Dirnhofer, S., Schwaller, J. and Skoda, R.C. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931-3940.
25. Shide, K., Kameda, T., Markovtsov, V., Shimoda, H.K., Tonkin, E., Fang, S., Liu, C., Gelman, M., Lang, W., Romero, J., McLaughlin, J., Bhamidipati, S., Clough, J., Low, C., Reitsma, A., Siu, S., Pine, P., Park, G., Torneros, A., Duan, M., Singh, R., Payan, D.G., Matsunaga, T., Hitoshi, Y. and Shimoda, K. (2011) R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood 117, 6866-6875.
26. Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., DeAngelo, D.J., Clark, J.J., Lee, S.J., Golub, T.R., Wadleigh, M., Gilliland, D.G. and Levine, R.L. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270.
27. Lasho, T.L., Pardanani, A. and Tefferi, A. (2010) LNK mutations in JAK2 mutation-negative erythrocytosis. N. Engl. J. Med. 363, 1189-1190.
28. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., Aziz, A., Godfrey, A.L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A.V., Guglielmelli, P., Tarpey, P., Harding, H.P., Fitzpatrick, J.D., Goudie, C.T., Ortmann, C.A., Loughran, S.J., Raine, K., Jones, D.R., Butler, A.P., Teague, J.W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.Q., Greaves, M., Bowen, D., Huntly, B.J., Harrison, C.N., Cross, N.C., Ron, D., Vannucchi, A.M., Papaemmanuil, E., Campbell, P.J. and Green, A.R. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391-2405.
29. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Them, N.C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G.I., Bagienski, K., Milanesi, C., Casetti, I.C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schonegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M. and Kralovics, R. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379-2390.
30. MacKenzie, K.L., Dolnikov, A., Millington, M., Shounan, Y. and Symonds, G. (1999) Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood 93, 2043-2056.
31. Cools, J., Stover, E.H., Boulton, C.L., Gotlib, J., Legare, R.D., Amaral, S.M., Curley, D.P., Duclos, N., Rowan, R., Kutok, J.L., Lee, B.H., Williams, I.R., Coutre, S.E., Stone, R.M., DeAngelo, D.J., Marynen, P., Manley, P.W., Meyer, T., Fabbro, D., Neuberg, D., Weisberg, E., Griffin, J.D. and Gilliland, D.G. (2003) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3, 459-469.
32. Uchida, T., Kitaura, J., Nakahara, F., Togami, K., Inoue, D., Maehara, A., Nishimura, K., Kawabata, K.C., Doki, N., Kakihana, K., Yoshioka, K., Izawa, K., Oki, T., Sada, A., Harada, Y., Ohashi, K., Katayama, Y., Matsui, T., Harada, H. and Kitamura, T. (2014) Hes1 up-regulation contributes to the development of FIP1L1-PDGFRApositive leukemia in blast crisis. Exp. Hematol. 42, 369-379.
33. Harada, H., Harada, Y., Tanaka, H., Kimura, A. and Inaba, T. (2003) Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 101, 673-680.
34. Gombart, A.F., Hofmann, W.K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S.H., Larsen, R.J., Asou, H., Miller, C.W., Hoelzer, D. and Koeffler, H.P. (2002) Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99, 1332-1340.
35. Hirai, H., Kobayashi, Y., Mano, H., Hagiwara, K., Maru, Y., Omine, M., Mizoguchi, H., Nishida, J. and Takaku, F. (1987) A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 327, 430-432.
36. Kaeferstein, A., Krug, U., Tiesmeier, J., Aivado, M., Faulhaber, M., Stadler, M., Krauter, J., Germing, U., Hofmann, W.K., Koeffler, H.P., Ganser, A. and Verbeek, W. (2003) The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia 17, 343-349.
37. Togami, K., Kitaura, J., Uchida, T., Inoue, D., Nishimura, K., Kawabata, K.C., Nagase, R., Horikawa, S., Izawa, K., Fukuyama, T., Nakahara, F., Oki, T., Harada, Y., Harada, H., Aburatani, H. and Kitamura, T. (2014) C-terminal mutant of C/EBP, (C/EBP,-Cm) down-regulates M-CSF receptor which is a potent accelerator in the progression of AML with C/EBP,-Cm B. Exp. Hematol. (in press).
38. Lin, Y.W., Slape, C., Zhang, Z. and Aplan, P.D. (2005) NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 106, 287-295.
39. Greenblatt, S., Li, L., Slape, C., Nguyen, B., Novak, R., Duffield, A., Huso, D., Desiderio, S., Borowitz, M.J., Aplan, P. and Small, D. (2012) Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood 119, 2883-2894.
40. Falini, B., Martelli, M.P., Bolli, N., Sportoletti, P., Liso, A., Tiacci, E. and Haferlach, T. (2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117, 1109-1120.
41. Noguera, N.I., Song, M.S., Divona, M., Catalano, G., Calvo, K.L., Garcia, F., Ottone, T., Florenzano, F., Faraoni, I., Battistini, L., Colombo, E., Amadori, S., Pandolfi, P.P. and Lo-Coco, F. (2013) Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 27, 1037-1043.
42. Wang, Z., Gall, J.M., Bonegio, R., Havasi, A., Illanes, K., Schwartz, J.H. and Borkan, S.C. (2013) Nucleophosmin, a critical Bax cofactor in ischemia-induced cell death. Mol. Cell. Biol. 33, 1916-1924.
43. Watanabe-Okochi, N., Yoshimi, A., Sato, T., Ikeda, T., Kumano, K., Taoka, K., Satoh, Y., Shinohara, A., Tsuruta, T., Masuda, A., Yokota, H., Yatomi, Y., Takahashi, K., Kitaura, J., Kitamura, T. and Kurokawa, M. (2013) The shortest isoform of C/EBPbeta, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model. Blood 121, 4142-4155.
44. Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., Arai, S., Sato, T., Shimabe, M., Nakagawa, M., Imai, Y., Kitamura, T. and Kurokawa, M. (2011) Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117, 3617-3628.
45. Watanabe-Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., Nakajima, H., Nosaka, T., Inaba, T. and Kitamura, T. (2008) AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111, 4297-4308.
46. Harada, Y., Inoue, D., Ding, Y., Imagawa, J., Doki, N., Matsui, H., Yahata, T., Matsushita, H., Ando, K., Sashida, G., Iwama, A., Kitamura, T. and Harada, H. (2013) RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 121, 3434-3446.
47. Liedtke, M. and Cleary, M.L. (2009) Therapeutic targeting of MLL. Blood 113, 6061-6068.
48. Krivtsov, A.V. and Armstrong, S.A. (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833.
49. Yokoyama, A. and Cleary, M.L. (2008) Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36-46.
50. Bernt, K.M., Zhu, N., Sinha, A.U., Vempati, S., Faber, J., Krivtsov, A.V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., Pollock, R.M., Richon, V.M., Kung, A.L. and Armstrong, S.A. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78.
51. The Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074.
52. Raza, A. and Galili, N. (2012) The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat. Rev. Cancer 12, 849-859.
53. Milosevic, J.D. and Kralovics, R. (2013) Genetic and epigenetic alterations of myeloproliferative disorders. Int. J. Hematol. 97, 183-197.
54. Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V. and Mozziconacci, M.J. (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10, 401.
55. Thiede, C. (2012) Mutant DNMT3A: teaming up to transform. Blood 119, 5615-5617.
56. Abdel-Wahab, O. and Levine, R. (2011) The spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell 20, 420-423.
57. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, S., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglino, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R. and Campbell, P.J. (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384-1395.
58. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. and Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69.
59. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., Hochhaus, A., Drexler, H.G., Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F.H. and Cross, N.C. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726.
60. Quivoron, C., Couronne, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., Godley, L., Opolon, P., Tilly, H., Solary, E., Duffourd, Y.,Dessen, P., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Vainchenker, W., Bastard, C., Mercher, T. and Bernard, O.A. (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38.
61. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., Nimer, S.D., Melnick, A., Godley, L.A., Aifantis, I. and Levine, R.L. (2011) Tet2 loss leads to increased hematopoietic stem cell selfrenewal and myeloid transformation. Cancer Cell 20, 11-24.
62. Muto, T., Sashida, G., Oshima, M., Wendt, G.R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., Nagae, G., Nakaseko, C., Yokote, K., Shimoda, K., Koseki, H., Suzuki, Y., Sugano, S., Aburatani, H., Ogawa, S. and Iwama, A. (2013) Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 210, 2627-2639.
63. Abdel-Wahab, O., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y.R., Kuscu, C., Hricik, T., Ndiaye-Lobry, D., Lafave, L.M., Koche, R., Shih, A.H., Guryanova, O.A., Kim, E., Li, S., Pandey, S., Shin, J.Y., Telis, L., Liu, J., Bhatt, P.K., Monette, S., Zhao, X., Mason, C.E., Park, C.Y., Bernstein, B.E., Aifantis, I. and Levine, R.L. (2013) Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641-2659.
64. Abdel-Wahab, O., Adli, M., LaFave, L.M., Gao, J., Hricik, T., Shih, A.H., Pandey, S., Patel, J.P., Chung, Y.R., Koche, R., Perna, F., Zhao, X., Taylor, J.E., Park, C.Y., Carroll, M., Melnick, A., Nimer, S.D., Jaffe, J.D., Aifantis, I., Bernstein, B.E. and Levine, R.L. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180-193.
65. Wang, J., Li, Z., He, Y., Pan, F., Chen, S., Rhodes, S., Nguyen, L., Yuan, J., Jiang, L., Yang, X., Weeks, O., Liu, Z., Zhou, J., Ni, H., Cai, C.L., Xu, M. and Yang, F.C. (2014) Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123, 541-553.
66. Cho, Y.S., Kim, E.J., Park, U.H., Sin, H.S. and Um, S.J. (2006) Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a liganddependent coactivator for retinoic acid receptor. J. Biol. Chem. 281, 17588-17598.
67. Fisher, C.L., Lee, I., Bloyer, S., Bozza, S., Chevalier, J., Dahl, A., Bodner, C., Helgason, C.D., Hess, J.L., Humphries, R.K. and Brock, H.W. (2010) Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev. Biol. 337, 9-15.
68. Xie, H., Xu, J., Hsu, J.H., Nguyen, M., Fujiwara, Y., Peng, C. and Orkin, S.H. (2014) Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stagespecific manner. Cell Stem Cell 14, 68-80.
69. Przychodzen, B., Jerez, A., Guinta, K., Sekeres, M.A., Padgett, R., Maciejewski, J.P. and Makishima, H. (2013) Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 122, 999-1006.
70. Inoue, D., Kitaura, J., Togami, K., Nishimura, K., Enomoto, Y., Uchida, T., Kagiyama, Y., Kawabata, K.C., Nakahara, F., Izawa, K., Oki, T., Maehara, A., Isobe, M., Tsuchiya, A., Harada, Y., Harada, H., Ochiya, T., Aburatani, H., Kimura, H., Thol, F., Heuser, M., Levine, R.L., Abdel-Wahab, O. and Kitamura, T. (2013) Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J. Clin. Invest. 123, 4627-4640.
71. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., Liu, L.X., Jiang, W.Q., Liu, J., Zhang, J.Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.H., Lei, Q.Y., Guan, K.L., Zhao, S.M. and Xiong, Y. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30.
72. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L. and Melnick, A. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567.
73. Chaturvedi, A., Araujo Cruz, M.M., Jyotsana, N., Sharma, A., Yun, H., Gorlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E.A., Jansen, E.E., Modlich, U., Li, Z., Sly, L.M., Geffers, R., Lindner, R., Manstein, D.J., Lehmann, U., Krauter, J., Ganser, A. and Heuser, M. (2013) Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122, 2877-2887.
74. Sasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F., Brenner, D., Brustle, A., Harris, I.S., Holmes, R., Wakeham, A., Haight, J., You-Ten, A., Li, W.Y., Schalm, S., Su, S.M., Virtanen, C., Reifenberger, G., Ohashi, P.S., Barber, D.L., Figueroa, M.E., Melnick, A., Zuniga-Pflucker, J.C. and Mak, T.W. (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659.
75. Kats, L.M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K., Karnik, R., Meissner, A., Small, D., Su, S.M., Yen, K., Zhang, J. and Pandolfi, P.P. (2014) Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance. Cell Stem Cell 14, 329-341.
76. Makishima, H., Yoshida, K., Nguyen, N., Przychodzen, B., Sanada, M., Okuno, Y., Ng, K.P., Gudmundsson, K.O., Vishwakarma, B.A., Jerez, A., Gomez-Segui, I., Takahashi, M., Shiraishi, Y., Nagata, Y., Guinta, K., Mori, H., Sekeres, M.A., Chiba, K., Tanaka, H., Muramatsu, H., Sakaguchi, H., Paquette, R.L., McDevitt, M.A., Kojima, S., Saunthararajah, Y., Miyano, S., Shih, L.Y., Du, Y., Ogawa, S. and Maciejewski, J.P. (2013) Somatic SETBP1 mutations in myeloid malignancies. Nat. Genet. 45, 942-946.
77. Thol, F., Suchanek, K.J., Koenecke, C., Stadler, M., Platzbecker, U., Thiede, C., Schroeder, T., Kobbe, G., Kade, S., Loffeld, P., Banihosseini, S., Bug, G., Ottmann, O., Hofmann, W.K., Krauter, J., Kroger, N., Ganser, A. and Heuser, M. (2013) SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 27, 2072-2075.
78. Piazza, R., Valletta, S., Winkelmann, N., Redaelli, S., Spinelli, R., Pirola, A., Antolini, L., Mologni, L., Donadoni, C., Papaemmanuil, E., Schnittger, S., Kim, D.W., Boultwood, J., Rossi, F., Gaipa, G., De Martini, G.P., di Celle, P.F., Jang, H.G., Fantin, V., Bignell, G.R., Magistroni, V., Haferlach, T., Pogliani, E.M., Campbell, P.J., Chase, A.J., Tapper, W.J., Cross, N.C. and Gambacorti-Passerini, C. (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat. Genet. 45, 18-24.
79. Sakaguchi, H., Okuno, Y., Muramatsu, H., Yoshida, K., Shiraishi, Y., Takahashi, M., Kon, A., Sanada, M., Chiba, K., Tanaka, H., Makishima, H., Wang, X., Xu, Y., Doisaki, S., Hama, A., Nakanishi, K., Takahashi, Y., Yoshida, N., Maciejewski, J.P., Miyano, S., Ogawa, S. and Kojima, S. (2013) Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45, 937-941.
80. Oakley, K., Han, Y., Vishwakarma, B.A., Chu, S., Bhatia, R., Gudmundsson, K.O., Keller, J., Chen, X., Vasko, V., Jenkins, N.A., Copeland, N.G. and Du, Y. (2012) Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood 119, 6099-6108.
81. Thorsteinsdottir, U., Mamo, A., Kroon, E., Jerome, L., Bijl, J., Lawrence, H.J., Humphries, K. and Sauvageau, G. (2002) Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99, 121-129.
82. Inoue, D., Kitaura, J., Matsui, H., Hou, H.-A., Chou, W.-C., Nagamachi, A., Kawabata, K.C., Togami, K., Nagase, R., Horikawa, S., Saika, M., Micol, J.-P., Hayashi, Y., Harada, Y., Harada, H., Inaba, T., Tien, H.-F., Abdel-Wahab, O. and Kitamura, T. (2014) SETBP1 mutations drive leukemic transformation in ASXL1-murtated MDS. Leukemia (in press).
83. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. and Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145, 788-800.
84. Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E.M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.K., Schlegelberger, B., Heuser, M. and Ganser, A. (2011) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J. Clin. Oncol. 29, 2499-2506.
85. Nikoloski, G., van der Reijden, B.A. and Jansen, J.H. (2012) Mutations in epigenetic regulators in myelodysplastic syndromes. Int. J. Hematol. 95, 8-16.
86. Xu, J., Wang, Y.Y., Dai, Y.J., Zhang, W., Zhang, W.N., Xiong, S.M., Gu, Z.H., Wang, K.K., Zeng, R., Chen, Z. and Chen, S.J. (2014) DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 111, 2620-2625.
87. Kim, S.J., Zhao, H., Hardikar, S., Singh, A.K., Goodell, M.A. and Chen, T. (2013) A DNMT3A mutation common in AML exhibits dominantnegative effects in murine ES cells. Blood 122, 4086-4089.
88. Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H.P., Klein, H.U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W. and Ogawa, S. (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247.
89. Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., Shlien, A., Groves, M.J., Forbes, S.A., Raine, K., Hinton, J., Mudie, L.J., McLaren, S., Hardy, C., Latimer, C., Della Porta, M.G., O'Meara, S., Ambaglio, I., Galli, A., Butler, A.P., Walldin, G., Teague, J.W., Quek, L., Sternberg, A., Gambacorti-Passerini, C., Cross, N.C., Green, A.R., Boultwood, J., Vyas, P., Hellstrom-Lindberg, E., Bowen, D., Cazzola, M., Stratton, M.R. and Campbell, P.J. (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616- 3627; quiz 3699.
90. Huntly, B.J., Shigematsu, H., Deguchi, K., Lee, B.H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, D., Williams, I.R., Akashi, K. and Gilliland, D.G. (2004) MOZ-TIF2, but not BCRABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596.
91. Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., Fulton, R., Magrini, V., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Fan, X., Grillot, M., Witowski, S., Heath, S., Frater, J.L., Eades, W., Tomasson, M., Westervelt, P., DiPersio, J.F., Link, D.C., Mardis, E.R., Ley, T.J., Wilson, R.K. and Graubert, T.A. (2012) Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090-1098.
92. Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., Beisel, C., Kralovics, R. and Skoda, R.C. (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220-2228.
93. Calabretta, B. and Perrotti, D. (2004) The biology of CML blast crisis. Blood 103, 4010-4022.
94. Perrotti, D., Jamieson, C., Goldman, J. and Skorski, T. (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 120, 2254-2264.
95. Ito, T., Kwon, H.Y., Zimdahl, B., Congdon, K.L., Blum, J., Lento, W.E., Zhao, C., Lagoo, A., Gerrard, G., Foroni, L., Goldman, J., Goh, H., Kim, S.H., Kim, D.W., Chuah, C., Oehler, V.G., Radich, J.P., Jordan, C.T. and Reya, T. (2010) Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466, 765-768.
96. Nakahara, F., Sakata-Yanagimoto, M., Komeno, Y., Kato, N., Uchida, T., Haraguchi, K., Kumano, K., Harada, Y., Harada, H., Kitaura, J., Ogawa, S., Kurokawa, M., Kitamura, T. and Chiba, S. (2010) Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 115, 2872-2881.
97. Bacher, U., Haferlach, T., Kern, W., Haferlach, C. and Schnittger, S. (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92, 744-752.